These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 12214069)

  • 1. Amyloid beta40/42 clearance across the blood-brain barrier following intra-ventricular injections in wild-type, apoE knock-out and human apoE3 or E4 expressing transgenic mice.
    Ji Y; Permanne B; Sigurdsson EM; Holtzman DM; Wisniewski T
    J Alzheimers Dis; 2001 Feb; 3(1):23-30. PubMed ID: 12214069
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A multifaceted role for apoE in the clearance of beta-amyloid across the blood-brain barrier.
    Bachmeier C; Paris D; Beaulieu-Abdelahad D; Mouzon B; Mullan M; Crawford F
    Neurodegener Dis; 2013; 11(1):13-21. PubMed ID: 22572854
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blood-brain barrier-associated pericytes internalize and clear aggregated amyloid-β42 by LRP1-dependent apolipoprotein E isoform-specific mechanism.
    Ma Q; Zhao Z; Sagare AP; Wu Y; Wang M; Owens NC; Verghese PB; Herz J; Holtzman DM; Zlokovic BV
    Mol Neurodegener; 2018 Oct; 13(1):57. PubMed ID: 30340601
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human apolipoprotein E4 alters the amyloid-beta 40:42 ratio and promotes the formation of cerebral amyloid angiopathy in an amyloid precursor protein transgenic model.
    Fryer JD; Simmons K; Parsadanian M; Bales KR; Paul SM; Sullivan PM; Holtzman DM
    J Neurosci; 2005 Mar; 25(11):2803-10. PubMed ID: 15772340
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transport pathways for clearance of human Alzheimer's amyloid beta-peptide and apolipoproteins E and J in the mouse central nervous system.
    Bell RD; Sagare AP; Friedman AE; Bedi GS; Holtzman DM; Deane R; Zlokovic BV
    J Cereb Blood Flow Metab; 2007 May; 27(5):909-18. PubMed ID: 17077814
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aging, gender and APOE isotype modulate metabolism of Alzheimer's Abeta peptides and F-isoprostanes in the absence of detectable amyloid deposits.
    Yao J; Petanceska SS; Montine TJ; Holtzman DM; Schmidt SD; Parker CA; Callahan MJ; Lipinski WJ; Bisgaier CL; Turner BA; Nixon RA; Martins RN; Ouimet C; Smith JD; Davies P; Laska E; Ehrlich ME; Walker LC; Mathews PM; Gandy S
    J Neurochem; 2004 Aug; 90(4):1011-8. PubMed ID: 15287908
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A nontransgenic mouse model shows inducible amyloid-beta (Abeta) peptide deposition and elucidates the role of apolipoprotein E in the amyloid cascade.
    Dolev I; Michaelson DM
    Proc Natl Acad Sci U S A; 2004 Sep; 101(38):13909-14. PubMed ID: 15365176
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interaction of nascent ApoE2, ApoE3, and ApoE4 isoforms expressed in mammalian cells with amyloid peptide beta (1-40). Relevance to Alzheimer's disease.
    Aleshkov S; Abraham CR; Zannis VI
    Biochemistry; 1997 Aug; 36(34):10571-80. PubMed ID: 9265639
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modulation of Alzheimer-like synaptic and cholinergic deficits in transgenic mice by human apolipoprotein E depends on isoform, aging, and overexpression of amyloid beta peptides but not on plaque formation.
    Buttini M; Yu GQ; Shockley K; Huang Y; Jones B; Masliah E; Mallory M; Yeo T; Longo FM; Mucke L
    J Neurosci; 2002 Dec; 22(24):10539-48. PubMed ID: 12486146
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease.
    Holtzman DM; Bales KR; Tenkova T; Fagan AM; Parsadanian M; Sartorius LJ; Mackey B; Olney J; McKeel D; Wozniak D; Paul SM
    Proc Natl Acad Sci U S A; 2000 Mar; 97(6):2892-7. PubMed ID: 10694577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Apolipoprotein E isoform-specific effects on lipoprotein receptor processing.
    Bachmeier C; Shackleton B; Ojo J; Paris D; Mullan M; Crawford F
    Neuromolecular Med; 2014 Dec; 16(4):686-96. PubMed ID: 25015123
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Apolipoprotein E4 inhibits γ-secretase activity via binding to the γ-secretase complex.
    Sun Y; Islam S; Gao Y; Nakamura T; Zou K; Michikawa M
    J Neurochem; 2023 Mar; 164(6):858-874. PubMed ID: 36582176
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A synthetic peptide blocking the apolipoprotein E/beta-amyloid binding mitigates beta-amyloid toxicity and fibril formation in vitro and reduces beta-amyloid plaques in transgenic mice.
    Sadowski M; Pankiewicz J; Scholtzova H; Ripellino JA; Li Y; Schmidt SD; Mathews PM; Fryer JD; Holtzman DM; Sigurdsson EM; Wisniewski T
    Am J Pathol; 2004 Sep; 165(3):937-48. PubMed ID: 15331417
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of ADAM10 promotes the clearance of Aβ across the BBB by reducing LRP1 ectodomain shedding.
    Shackleton B; Crawford F; Bachmeier C
    Fluids Barriers CNS; 2016 Aug; 13(1):14. PubMed ID: 27503326
    [TBL] [Abstract][Full Text] [Related]  

  • 15. C-terminal-truncated apolipoprotein (apo) E4 inefficiently clears amyloid-beta (Abeta) and acts in concert with Abeta to elicit neuronal and behavioral deficits in mice.
    Bien-Ly N; Andrews-Zwilling Y; Xu Q; Bernardo A; Wang C; Huang Y
    Proc Natl Acad Sci U S A; 2011 Mar; 108(10):4236-41. PubMed ID: 21368138
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Apolipoprotein E is essential for amyloid deposition in the APP(V717F) transgenic mouse model of Alzheimer's disease.
    Bales KR; Verina T; Cummins DJ; Du Y; Dodel RC; Saura J; Fishman CE; DeLong CA; Piccardo P; Petegnief V; Ghetti B; Paul SM
    Proc Natl Acad Sci U S A; 1999 Dec; 96(26):15233-8. PubMed ID: 10611368
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic associations between cathepsin D exon 2 C-->T polymorphism and Alzheimer's disease, and pathological correlations with genotype.
    Davidson Y; Gibbons L; Pritchard A; Hardicre J; Wren J; Tian J; Shi J; Stopford C; Julien C; Thompson J; Payton A; Thaker U; Hayes AJ; Iwatsubo T; Pickering-Brown SM; Pendleton N; Horan MA; Burns A; Purandare N; Lendon CL; Neary D; Snowden JS; Mann DM
    J Neurol Neurosurg Psychiatry; 2006 Apr; 77(4):515-7. PubMed ID: 16543533
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lipidation of apolipoprotein E influences its isoform-specific interaction with Alzheimer's amyloid beta peptides.
    Tokuda T; Calero M; Matsubara E; Vidal R; Kumar A; Permanne B; Zlokovic B; Smith JD; Ladu MJ; Rostagno A; Frangione B; Ghiso J
    Biochem J; 2000 Jun; 348 Pt 2(Pt 2):359-65. PubMed ID: 10816430
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human and murine ApoE markedly alters A beta metabolism before and after plaque formation in a mouse model of Alzheimer's disease.
    Fagan AM; Watson M; Parsadanian M; Bales KR; Paul SM; Holtzman DM
    Neurobiol Dis; 2002 Apr; 9(3):305-18. PubMed ID: 11950276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Apolipoprotein E4 influences amyloid deposition but not cell loss after traumatic brain injury in a mouse model of Alzheimer's disease.
    Hartman RE; Laurer H; Longhi L; Bales KR; Paul SM; McIntosh TK; Holtzman DM
    J Neurosci; 2002 Dec; 22(23):10083-7. PubMed ID: 12451108
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.